Unlocked Labs develops a single-strain probiotic, Strain OX164, specifically engineered to degrade oxalic acid, a metabolic waste product that can negatively impact kidney health. This targeted probiotic formulation activates in the intestine, converting oxalic acid into harmless byproducts for easier elimination from the body.
Funding
$520K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Elevated levels of oxalic acid, a metabolic waste product primarily derived from food, can place undue stress on the kidneys and negatively impact overall well-being. Current probiotic solutions often consist of multi-strain blends intended for general gut health, lacking the specificity needed to effectively address oxalic acid levels.
Solution
Unlocked Labs offers Strain OX164, a single-strain probiotic meticulously engineered to target and degrade oxalic acid within the intestine. This probiotic converts oxalic acid into harmless byproducts that are easily eliminated from the body, helping to maintain healthy oxalic acid levels. The proprietary formulation ensures the probiotic remains shelf-stable and activates upon reaching the intestine, delivering a targeted approach to managing oxalic acid.
Target Audience
Individuals seeking to maintain healthy oxalic acid levels and support kidney health through targeted probiotic supplementation are the primary customers.
Features
- Single-strain probiotic (Strain OX164) specifically selected for oxalic acid degradation
- Contains oxalate decarboxylase, an enzyme that converts oxalic acid into harmless byproducts
- Proprietary formulation ensures shelf stability at room temperature
- Designed for daily use, with a single-dose sachet for easy consumption
- No refrigeration required, making it convenient for travel and on-the-go use
- Undergoing third-party safety testing according to OECD guidelines for New Dietary Ingredients